

Press Release
Västra Frölunda, Sweden, May 3, 2012

ARTIMPLANT THREE - MONTH REPORT 2012

- Net revenue amounted to SEK 6.8 million (5.4), an increase of 27 percentage points.
- The net loss totaled SEK 2.3 million (3.9).
- Earnings per stock unit amounted to SEK -0.01 (-0.03).
- The result has improved by SEK 1.6 million compared to the corresponding period last year.
- Positive sales trend on all markets. Own sales in the USA increased by 86 percentage points and in Europe by 42 percentage points.
- A new stock issue during the first quarter generated capital input for the Company of SEK 23.7 million before issue costs.

EVENTS AFTER THE PERIOD-END

- The agreement with Biomet was terminated in April.

** Figures in brackets refer to the corresponding period last year.*

N. B. This is a translation from Swedish. The Swedish version shall always take precedence.

For further information, please contact:

Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html



Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
SWEDEN

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Reg. No. 556404-8394

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[®], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 3, 2012 at 3 PM (Swedish time).